Abstract: Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e.g., metastatic breast cancer, through the determination of Lamellipodin protein or gene expression levels in the subject.

Abstract: Embodiments of the invention provide a method and apparatus that allow for a personalised heart tissue model to be generated, that models heart tissue electrophysiology behaviour at a personalised level, based upon activation measurements of an individual subject's heart in response to a number of predefined pacing protocols. The activation measurements are collected using a catheter placed onto the subject's heart, which is then paced via the catheter in accordance with the pacing protocols, and activation times of the heart tissue recorded. The activation measurements are used to generate a personalised tissue model, for example, by parameter matching the activation measurements with a large number of predefined sets of activation measurements, to determine the best-fit set; the best-fit set is then used as a personalised heart tissue model in a two or three-dimensional simulation of heart tissue activation in response to simulated stimulation.

Abstract: In a method and apparatus for performing magnetic resonance (MR) imaging for generating multiple T1 maps of separate regions of interest of a subject along a first spatial axis, multiple MR pulse sequences are generated, each MR pulse sequence being for imaging a respective one of the separate regions of interest of the subject. In order to generate each of the plurality of MR pulse sequences, a spatially selective preparation pulse is generated exciting the region of interest of the subject and a number of imaging sequences that follow the application of the spatially selective preparation pulse are generated. MR imaging data are acquired during the generation of the multiple imaging sequences. The multiple MR pulse sequences are generated during a period not exceeding 30 seconds.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RARP?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.

Abstract: A pharmaceutically acceptable small molecule which inhibits GSK-3 activity, such as BIO, CHIR99021 or tideglusib; are used in the repair or regeneration of dentine. Combinations with matrix materials forming dental implants are also described and claimed.

Abstract: Disclosed herein are positive allosteric modulators of melanocortin receptor and methods of using such modulators.

Abstract: A plasmonic switching device and method of providing a plasmonic switching device. An example device includes a resonant cavity and an electromagnetic radiation feed arranged to couple electromagnetic radiation into the resonant cavity and at least one plasmonic mode. The resonant cavity is arranged to be switchable between: a first state in which the resonant cavity has an operational characteristic selected to allow resonance of the electromagnetic radiation at a frequency of the at least one plasmonic mode; and a second state in which the operational characteristic of the resonant cavity is adjusted to inhibit resonance of the electromagnetic radiation at a frequency of the at least one plasmonic mode.

Abstract: Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same.

Abstract: Some embodiments are directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein determining the level of octameric PTX3 includes measuring the total amount of PTX3 present, and measuring the amount of octameric PTX3 present, and calculating the proportion of total PTX3 which is present as octamer, wherein if the proportion of octameric PTX3 is greater than 50%, the subject is identified as a likely non-survivor. Some embodiments are also directed to a method of collecting information useful in predicting clinical outcome in a subject, the method including providing a sample from said subject, and determining the level of octameric PTX3 in said sample, wherein an elevated level of octameric PTX3 compared to a reference level indicates a reduced likelihood of survival.

Abstract: The present invention relates to a predictive diagnostic method for identifying whether a patient will develop metabolic syndrome and/or type-2 diabetes in the future. In particular, the invention relates to a method for identifying a subject which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e. determining/measuring/quantifying) in a sample obtained from a test subject the amount of miR-122; and (b) identifying (i.e. detecting) a subject, which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein an increased amount of miR-122 as compared to the amount of miR-122 of a healthy reference population indicates a risk for developing metabolic syndrome and/or type-2 diabetes. Another aspect of the invention relates to a method for monitoring the therapeutic success during the treatment of metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e.

Abstract: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin:total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.

Abstract: The invention relates to the use of a poly(ADP ribose) polymerase (PARP) inhibitor and/or a tetracycline, for treating, preventing or ameliorating medial vascular calcification, and to pharmaceutical compositions comprising PARP inhibitors or tetracycline.

Abstract: A plasmon generator comprises a plasmon supporting surface and first and second quantum systems respectively defining first and second quantum states with a tunneling junction being present between the first and second quantum systems, the first and second quantum systems being present in an electric circuit to generate a tunneling current between the first and second quantum systems, whereby electrons tunneling between said first and second quantum states loose energy in the process and generate plasmons at the plasmon supporting surface.

Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.

Abstract: The invention relates to a specific peptide combination. The peptide combination may be present in a pharmaceutically acceptable composition. The peptide combination can be used in the therapy or prevention of Type 1 Diabetes (TID). The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the specific peptide combination.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RAR?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.

Abstract: The invention relates to a phantom device for reproducing the fluid perfusion in a body, said device comprising a phantom organ that may be introduced into a scanner, said phantom organ comprising a housing in which are defined a plurality of fluid channels, suitably of differing cross-sectional areas; a feed tube arranged to supply liquid to a first end of all of said channels and means for collecting liquid from the other end of the channels.

Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.

Abstract: Periodic data is analyzed by obtaining a vector of delay coordinates for each one of a plurality of samples of the periodic data in a time window, and transforming each of the vectors into a coordinate system comprising a plurality of predefined vectors, to obtain a projection of an attractor of the periodic data along one of the predefined vectors. The periodic data may be physiological data. Information representing one or more characteristics of the obtained attractor, which is of diagnostic value, is then displayed to enable a diagnosis.

Abstract: The present invention provides a method and system to reduce the problem of signal dropout in data acquired using gradient-echo and asymmetric spin-echo magnetic resonance techniques, caused by linear susceptibility gradients in the direction of slice-selection. Specifically an algorithm is used to determine the optimal parameters of a tailored radiofrequency pulse along with the accompanying slice-selection and slice-refocusing gradients to correct this signal dropout.